ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025
Younger age as a risk factor for rash development in pemetrexed and carboplatin treatment with dexamethasone prophylaxis.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCarboplatin (CBDCA) plus pemetrexed (PEM) is one of the most effective regimens for treating thoracic cancer. Rash, which is mainly caused by PEM, occurs in 15-30% of patients. Dexamethasone administration for 3 days is recommended to manage rash, chemotherapy-induced nausea, and vomiting in this regimen. However, the nature of the PEM-induced rashes is not fully understood. Consequently, we aimed to identify the risk factors associated with rash development under dexamethasone prophylaxis in CBDCA + PEM treatment.
methodsPatients with thoracic cancer who underwent CBDCA + PEM treatment (n = 133) were retrospectively assessed. The primary endpoint of the present study was to identify the risk factor(s) for the incidence of all-grade rash in the first cycle. Factors affecting the incidence during all treatment cycles were also evaluated.
resultsThe incidence of all-grade rash in the first cycle was 24.1%, including 16.5% for grade 1, 5.3% for grade 2, and 2.3% for grade 3, respectively. Moreover, that in all cycles, it was 27.1%, with 18.8% for grade 1, 6.0% for grade 2, and 2.3% for grade 3. Multivariate logistic regression analyses identified that age < 65 years was the singular independent risk factor for rash development in the first and all cycles (adjusted odds ratio, 2.79; 95% confidence interval, 1.17-6.67; p = 0.02 for the first cycle, 3.03, 1.29-7.09; p = 0.01 for all cycles).
conclusionOur study revealed that patients aged < 65 years were at a significantly higher risk of rash development during CBDCA + PEM chemotherapy with dexamethasone prophylaxis than patients ≥ 65 years of age.
Indexed as
Identifiers
41074948What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.